Ad hoc-Mitteilungen
• 13:35 IGEA Pharma N • 07.08.20 IGEA Pharma N • 07.08.20 STS Group • 07.08.20 The Social Chain AG • 07.08.20 EUROCASTLE INVESTMENT LTD • 07.08.20 REO SPANIEN PRO ANL 15/19 • 07.08.20 Klaipedos Nafta • 07.08.20 CRYPTOLOGY ASSET GRP EO 1 • 07.08.20 NEXR Technologies • 07.08.20 Solutiance •
  • Startseite
  • Aktien
  • Indizes
  • SMI
  • News
  • Ad-hocs

    • SMI News

    10.105,18 -0,15% -15,202
    07.08.20 22:14:33 ARIVA Indikation Indizes | Mehr Kurse »
    WKN: 969000
    ISIN: CH0009980894
    Typ: Index
    Jetzt für 0€ handeln

    Ad-hocs

      
    < Zurück < Zurück
    von 25
    Weiter > Weiter >
    < Zurück < Zurück
    von 25
    Weiter > Weiter >
    30.07.20 - GlobeNewswire
    Nestlé reports half-year results for 2020
    11.06.20 - GlobeNewswire
    Nestlé sharpens water focus on international, premium mineral and functional brands while exploring strategic options for parts of North American business
    24.04.20 - GlobeNewswire
    Nestlé reports three-​month sales for 2020, provides COVID-19 update
    23.04.20 - GlobeNewswire
    Nestlé S.A. Annual General Meeting
    24.03.20 - GlobeNewswire
    Nestlé S.A. maintains date of Annual General Meeting, changes format in light of coronavirus
    24.03.20 - GlobeNewswire
    Nestlé highlights innovation, digitalization and sustainability in 2019 Annual Report
    13.02.20 - GlobeNewswire
    Nestlé proposes Hanne Jimenez de Mora as a new independent member of the Board of Directors
    13.02.20 - GlobeNewswire
    Nestlé reports full-year results for 2019
    29.01.20 - GlobeNewswire
    Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
    Full year net sales for c ontinuing operations 1 up 9% (cc 2 , +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 ...
    29.01.20 - GlobeNewswire
    Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-​steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe
    Der Nettoumsatz der fortzuführenden Geschäftsbereiche 1 steigt 2019 um 9% (kWk 2 , +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von ...
    27.01.20 - GlobeNewswire
    Nestlé acquires Zenpep, expanding its medical nutrition business
    06.01.20 - GlobeNewswire
    Novartis completes tender offer for all outstanding shares of The Medicines Company
    Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-​owned ...
    30.12.19 - GlobeNewswire
    Nestlé completes CHF 20 billion share buyback program, will start new share buyback program of up to CHF 20 billion
    19.12.19 - GlobeNewswire
    Nestlé to sell 60% stake of Herta and create a joint venture with Casa Tarradellas
    16.12.19 - GlobeNewswire
    Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
    Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events ...
    11.12.19 - GlobeNewswire
    Nestlé makes strategic move to create global leader in ice cream
    05.12.19 - GlobeNewswire
    Novartis tender offer for The Medicines Company commences
    Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-​owned subsidiary, Medusa Merger Corporation, a Delaware corporation ...
    24.11.19 - GlobeNewswire
    Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-​lowering therapy to address leading global cause of death
    Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do ...
    15.11.19 - GlobeNewswire
    New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
    Sickle cell pain crises are unpredictable, severe events associated with life-​threatening complications 1 Adakveo reduced the annual rate of sickle cell pain crises by 45% ...
    01.11.19 - GlobeNewswire
    Novartis Cosentyx® shows encouraging results versus Humira®* from first-​of-its-kind head-​to-head trial in psoriatic arthritis
    Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira ® * ...
    30.10.19 - GlobeNewswire
    Novartis announces AVXS-101 intrathecal study update
    FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-​clinical animal study Adverse events that might be expected ...
    22.10.19 - GlobeNewswire
    Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
    Continuing operations 2 net sales up 13% (cc 1 , +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions ...
    22.10.19 - GlobeNewswire
    Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-​wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-​Einführung von Beovu
    Der Nettoumsatz der fortzuführenden Geschäftsbereiche 2 steigt aufgrund folgender Beiträge um 13% (kWk 1 , +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millione...
    17.10.19 - GlobeNewswire
    Nestlé announces changes to its waters business, establishes Group Strategy and Business Development function
    Nestlé announces changes to its waters business, establishes Group Strategy and Business Development function
    17.10.19 - GlobeNewswire
    Nestlé reports nine-​month sales for 2019
    02.10.19 - GlobeNewswire
    Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
    Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-​radiographic axial spondyloarthritis (nr-axSpA)[1] ...
    17.09.19 - GlobeNewswire
    Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
    Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-​radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also ...
    30.08.19 - GlobeNewswire
    Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-​to-head Phase III multiple sclerosis studies
    In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio ®* (teriflunomide) in patients with relapsing forms of MS ...
    05.11.18 - GlobeNewswire
    Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis R&D update highlights industry ...
    10.10.18 - GlobeNewswire
    Novartis announces new data from the first direct head-​to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis announces new data from the ...
    20.09.18 - GlobeNewswire
    Nestlé to sharpen its Nutrition, Health and Wellness strategic focus, will explore strategic options for Nestlé Skin Health
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Nestlé to sharpen its Nutrition, Health and ...
    17.09.18 - GlobeNewswire
    Nestlé agrees to sell Gerber Life Insurance Co. to Western & Southern Financial Group
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Nestlé agrees to sell Gerber Life ...
    11.09.18 - GlobeNewswire
    Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Alcon bestätigt vor dem vorgeschlagenen ...
    11.09.18 - GlobeNewswire
    Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Alcon confirms commitment to ...
    29.08.18 - GlobeNewswire
    Alcon announces voluntary global market withdrawal of CyPass Micro-​Stent for surgical glaucoma
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Alcon announces voluntary global market ...
    28.08.18 - GlobeNewswire
    Nestlé and Starbucks close deal for the perpetual global license of Starbucks Consumer Packaged Goods and Foodservice products
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Nestlé and Starbucks close deal for the ...
    27.08.18 - GlobeNewswire
    Novartis erhält die Zulassung für seine CAR-​T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis erhält die Zulassung für seine ...
    27.08.18 - GlobeNewswire
    Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis receives European Commission ...
    25.08.18 - GlobeNewswire
    Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis announces new data that show ...
    26.07.18 - GlobeNewswire
    Nestlé reports half-year results for 2018
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Nestlé reports half-year results for 2018 ...
    23.07.18 - GlobeNewswire
    Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis renews drug donation of ...
    19.07.18 - GlobeNewswire
    Novartis demonstrates commitment to lead immuno-​dermatology by in-​licensing IL-17C compound for atopic dermatitis
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis demonstrates commitment to ...
    02.07.18 - GlobeNewswire
    Nestlé Outlines Value Creation Progress
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Nestlé Outlines Value Creation Progress ...
    16.05.18 - GlobeNewswire
    Novartis kündigt Veränderungen in der Geschäftsleitung an
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Novartis kündigt Veränderungen in der ...
    16.05.18 - GlobeNewswire
    Novartis announces changes to the Executive Committee
    Novartis announces changes to the Executive Committee body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; ...
    18.04.18 - GlobeNewswire
    Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
    body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-​color:black;} td.hugin { padding: 3px; border-​color:black;} Sandoz signs agreement with Pear ...
    16.04.18 - GlobeNewswire
    Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
    Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes body { font-​family ...
    27.03.18 - GlobeNewswire
    Novartis verkauft Beteiligung an Consumer-​Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren
    Novartis verkauft Beteiligung an Consumer-​Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren body { font-​family: Arial, ...
    27.03.18 - GlobeNewswire
    Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
    Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} tabl...
    12.03.18 - GlobeNewswire
    Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an
    Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an body { font-​family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { ...
    < Zurück < Zurück
    von 25
    Weiter > Weiter >

    Newssuche

      

    Videos

      
    07.08.20 -2,45%
    Die meistgehandelten Aktien des Tages - Apple, Tencent, Teamviewer
    Franziska Schimke blickt auf die meistgehandelten Werte beim Onlinebroker Flatex. Welche Aktien werden ... Mehr »